Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant PD-1 antibody plus lenvatinib after R0 resection following conversion therapy in HCC with pCR/MPR
ChiCTR2100051789Phase 2Recruiting
- Sponsor
- Fujian Provincial Hospital
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab and lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Fujian Provincial Hospital. Primary endpoint: Progression-free survival. Started Jun 2022; status: recruiting.
02
Drugs
sintilimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100051789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051789.